← REGULATORY CHANGES
FEDERAL REGISTER · RULESeptember 17, 2024IN FORCE

Medical Devices; Immunology and Microbiology Devices; Classification of the Quantitative Viral Nucleic Acid Test for Transplant Patient Management

What this record is not

Document details are published in the U.S. Federal Register; SPEQ surfaces them for reference and is not affiliated with or endorsed by the FDA or the Office of the Federal Register. The authoritative text is on federalregister.gov.

STATUSIN FORCE
EFFECTIVESep 17, 2024
COMMENTS CLOSE—
APPLIES TO · SPEQ TAGDevice
Document type
Rule
Agency
Health and Human Services Department
Published
September 17, 2024
Effective
September 17, 2024
Document number
2024-21086
CFR references
21 CFR 866
Docket
FDA-2024-N-4084
ABSTRACT

The Food and Drug Administration (FDA, Agency, or we) is classifying the quantitative viral nucleic acid test for transplant patient management into class II (special controls). The special controls that apply to the device type are identified in this order and will be part of the codified language for the quantitative viral nucleic acid test for transplant patient management's classification. We are taking this action because we have determined that classifying the device into class II (special controls) will provide a reasonable assurance of safety and effectiveness of the device. We believe this action will also enhance patients' access to beneficial innovative devices.

Abstract as published in the Federal Register.